BlackRock
ORIC icon

BlackRock’s Oric Pharmaceuticals ORIC Stock Holding History

BlackRock’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.9M Buy
6,823,973
+839,421
+14% +$7.61M ﹤0.01% 2406
2026
Q1 		$75.8M Buy
5,984,552
+109,499
+2% +$1.24M ﹤0.01% 2273
2025
Q4 		$48.1M Buy
5,875,053
+598,433
+11% +$6.89M ﹤0.01% 2539
2025
Q3 		$63.3M Buy
5,276,620
+1,198,635
+29% +$12.6M ﹤0.01% 2364
2025
Q2 		$41.4M Sell
4,077,985
-1,357,102
-25% -$9.11M ﹤0.01% 2566
2025
Q1 		$30.3M Buy
5,435,087
+322,053
+6% +$2.82M ﹤0.01% 2691
2024
Q4 		$41.3M Buy
5,113,034
+11,217
+0.2% +$103K ﹤0.01% 2574
2024
Q3 		$52.3M Buy
5,101,817
+270,937
+6% +$2.68M ﹤0.01% 2445
2024
Q2 		$34.2M Buy
4,830,880
+1,652,695
+52% +$14.8M ﹤0.01% 2657
2024
Q1 		$43.7M Buy
3,178,185
+82,537
+3% +$980K ﹤0.01% 2517
2023
Q4 		$28.5M Sell
3,095,648
-636,958
-17% -$4.61M ﹤0.01% 2809
2023
Q3 		$22.6M Buy
3,732,606
+1,157,325
+45% +$9.48M ﹤0.01% 2870
2023
Q2 		$20M Buy
2,575,281
+1,884,767
+273% +$10.7M ﹤0.01% 3041
2023
Q1 		$3.94M Sell
690,514
-107,874
-14% -$564K ﹤0.01% 3735
2022
Q4 		$4.7M Sell
798,388
-240,554
-23% -$812K ﹤0.01% 3750
2022
Q3 		$3.32M Buy
1,038,942
+239,601
+30% +$959K ﹤0.01% 3937
2022
Q2 		$3.58M Sell
799,341
-1,574,559
-66% -$6.28M ﹤0.01% 3969
2022
Q1 		$12.7M Sell
2,373,900
-41,447
-2% -$373K ﹤0.01% 3454
2021
Q4 		$35.5M Buy
2,415,347
+4,805
+0.2% +$74.9K ﹤0.01% 2907
2021
Q3 		$50.4M Buy
2,410,542
+140,232
+6% +$2.84M ﹤0.01% 2660
2021
Q2 		$40.2M Buy
2,270,310
+359,957
+19% +$7.89M ﹤0.01% 2838
2021
Q1 		$46.8M Buy
1,910,353
+31,445
+2% +$994K ﹤0.01% 2662
2020
Q4 		$63.6M Buy
1,878,908
+1,104,701
+143% +$31.7M ﹤0.01% 2335
2020
Q3 		$19.4M Sell
774,207
-94,734
-11% -$2.25M ﹤0.01% 2871
2020
Q2 		$29.3M Buy
+868,941
New +$27.7M ﹤0.01% 2597

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIHC Capital Management Central $104M AUM

BlackRock's ORIC Position: Q2 2026 in Review

BlackRock increased its Oric Pharmaceuticals (ORIC) stake by 14% in Q2 2026, buying an estimated $7.61M and bringing the position to 6,823,973 shares worth $73.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2406.

BlackRock first reported a position in ORIC in Q2 2020 and has held it in 25 quarters since. The position peaked at $75.8M in Q1 2026. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • BlackRock held 6,823,973 shares of Oric Pharmaceuticals worth $73.9M as of Q2 2026.
  • BlackRock bought 839,421 Oric Pharmaceuticals shares in Q2 2026, an estimated $7.61M.
  • Oric Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2406 holding.
  • BlackRock first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • BlackRock's Oric Pharmaceuticals position peaked at $75.8M in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.